Nyxoah (NYXH) Expected to Post Earnings on Thursday

Nyxoah (NASDAQ:NYXH) is expected to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.3510) per share and revenue of $11.00 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Nyxoah (NASDAQ:NYXH) last released its earnings results on Thursday, August 6th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.20). The company had revenue of $8.76 million for the quarter, compared to the consensus estimate of $8.64 million. Nyxoah had a negative return on equity of 178.90% and a negative net margin of 443.16%. On average, analysts expect Nyxoah to post ($1.46) EPS for the current fiscal year and ($0.80) EPS for the next fiscal year.

Nyxoah Stock Up 1.0%

NYXH stock opened at $0.88 on Tuesday. The company has a quick ratio of 2.31, a current ratio of 2.38 and a debt-to-equity ratio of 0.44. The business has a 50 day moving average price of $1.33 and a two-hundred day moving average price of $2.50. The company has a market cap of $34.11 million, a price-to-earnings ratio of -0.35 and a beta of 1.65. Nyxoah has a twelve month low of $0.80 and a twelve month high of $5.92.

Analyst Upgrades and Downgrades

NYXH has been the subject of several analyst reports. Cantor Fitzgerald decreased their target price on shares of Nyxoah to $3.00 and set an “overweight” rating for the company in a research note on Tuesday, October 27th. Piper Sandler reaffirmed an “overweight” rating and set a $6.00 price target (down from $7.00) on shares of Nyxoah in a research report on Thursday, August 6th. Wall Street Zen cut shares of Nyxoah from a “hold” rating to a “sell” rating in a research note on Sunday, August 9th. Raymond James Financial set a $3.00 price objective on shares of Nyxoah in a research report on Tuesday, October 27th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Nyxoah in a research note on Wednesday, August 19th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Nyxoah currently has a consensus rating of “Hold” and an average price target of $3.55.

About Nyxoah

Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA), a common sleep-related breathing disorder. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares trade on the Nasdaq under the symbol NYXH.

Nyxoah’s principal product is the Genio system, an implantable, rechargeable device designed to treat OSA through hypoglossal nerve stimulation. The system is intended to help maintain an open airway during sleep by stimulating the nerves that control the tongue and related upper-airway muscles.